{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=58",
    "query": {
      "condition": "Skin and Connective Tissue Disease",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 15619,
    "total_pages": 1562,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=59&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+and+Connective+Tissue+Disease&page=57&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T12:59:41.796Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00898508",
      "title": "Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "proteomic profiling",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "fluorescent antibody technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "liquid chromatography",
          "type": "OTHER"
        },
        {
          "name": "mass spectrometry",
          "type": "OTHER"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "20 Years and older · Female only"
      },
      "enrollment_count": 563,
      "start_date": "2005-08-19",
      "completion_date": "2019-06-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Duarte, California • Pasadena, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00898508"
    },
    {
      "nct_id": "NCT03070925",
      "title": "Prospective PuraPly™ AM Case Series Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pressure Ulcers",
        "Venous Ulcers",
        "Diabetic Ulcers",
        "Surgical Wounds",
        "Trauma Wounds"
      ],
      "interventions": [
        {
          "name": "PuraPly™ Antimicrobial Wound Matrix",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Organogenesis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2016-11",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2017-08-31",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 1,
      "location_summary": "Lake Success, New York",
      "locations": [
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070925"
    },
    {
      "nct_id": "NCT05537740",
      "title": "A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BAY3375968",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2022-10-11",
      "completion_date": "2027-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05537740"
    },
    {
      "nct_id": "NCT02268474",
      "title": "Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Erythematotelangiectatic Rosacea",
        "Papulopustular Rosacea"
      ],
      "interventions": [
        {
          "name": "532nm KTP Laser vs 595nm Pulse Dye Laser",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cutera Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 80 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2014-09",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02268474"
    },
    {
      "nct_id": "NCT03536897",
      "title": "IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "IORT",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Mount Carmel Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "65 Years and older · Female only"
      },
      "enrollment_count": 168,
      "start_date": "2018-02-27",
      "completion_date": "2028-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03536897"
    },
    {
      "nct_id": "NCT06422455",
      "title": "Access to Genetic Testing in Underserved Patients With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Carcinoma",
        "Male Breast Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Prostate Carcinoma",
        "Ovarian Carcinoma",
        "Pancreatic Exocrine Neoplasm",
        "Stage IVB Prostate Cancer American Joint Committee on Cancer v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Genetic Counseling",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2023-10-24",
      "completion_date": "2028-10-24",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Rochester, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06422455"
    },
    {
      "nct_id": "NCT00632489",
      "title": "LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LBH589",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-05",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00632489"
    },
    {
      "nct_id": "NCT00347568",
      "title": "BC-DAISY: A Breast Cancer Decision Aid System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TX-plore",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rhode Island Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 75 Years · Female only"
      },
      "enrollment_count": 195,
      "start_date": "2006-07",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2012-06-05",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00347568"
    },
    {
      "nct_id": "NCT01498874",
      "title": "Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "gevokizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XOMA (US) LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2011-12",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 19,
      "location_summary": "Hot Springs, Arkansas • Riverside, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498874"
    },
    {
      "nct_id": "NCT01955460",
      "title": "Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "NGFR-transduced Autologous T Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 34,
      "start_date": "2014-10-15",
      "completion_date": "2027-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-06T12:59:41.796Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01955460"
    }
  ]
}